Comment: Abbott seeks solution to potential St. Jude regulatory hurdle
Abbott Laboratories will likely have to offload assets before it can complete a $25 billion acquisition of medical device maker St. Jude Medical, in a move to ward off regulatory concerns...To view the full article, register now.
Already a subscriber? Click here to view full article